**Table S1. Risk factors for development of WRN**

|  |  |  |
| --- | --- | --- |
|  | **Univariate Analysis** | **Multivariate Analysis\*** |
|  | **OR (95% CI)** | ***P*-value** | **OR (95% CI)** | ***P*-value** |
| **Male**  | 0.89 (0.70 – 1.15)  | 0.374 |  |  |
| **Age** | 1.01 (1.00 – 1.02)  | 0.028 |  |  |
| **Hypertension**  | 1.18 (0.84 – 1.66)  | 0.342 |  |  |
| **Diabetes mellitus**  | 1.26 (0.98 – 1.62)  | 0.070 |  |  |
| **Coronary artery disease** | 1.35 (1.02 – 1.78)  | 0.035 |  |  |
| **Peripheral vascular disease** | 1.39 (0.87 – 2.22)  | 0.168 |  |  |
| **Chronic liver disease** | 1.18 (0.66 – 2.10)  | 0.586 |  |  |
| **Respiratory disease** | 1.01 (0.69 – 1.46)  | 0.980 |  |  |
| **Atrial fibrillation** | 0.58 (0.45 – 0.75)  | <0.001 | 0.56 (0.40 – 0.80)  | 0.001  |
| **Deep vein thrombosis** | 1.33 (0.95 – 1.85)  | 0.097 |  |  |
| **Pulmonary embolism**  | 0.98 (0.66 – 1.44)  | 0.915 |  |  |
| **Valvular disease** | 1.22 (0.91 – 1.64)  | 0.176 |  |  |
| **Cerebrovascular attack** | 0.83 (0.65 – 1.07)  | 0.160 |  |  |
| **Thyroid disease** | 0.73 (0.41 – 1.30)  | 0.279 |  |  |
| **Malignancy** | 1.08 (0.80 – 1.44)  | 0.632 |  |  |
| **Congestive heart failure** | 1.49 (1.16 – 1.92)  | 0.002 | 1.64 (1.19 – 2.25)  | 0.002  |
| **Chronic kidney disease**  | Stage 1 - 2 | Reference |  |  |  |
|  | Stage 3 | 1.33 (1.00-1.78) | 0.051 |  |  |
|  | Stage 4 - 5 | 2.59 (1.67-4.02) | <0.001 |  |  |
| **Prothrombin time (at INR > 3.0)** | 1st [3.01 – 3.18] | Reference |  |  |  |
|  | 2nd [3.19 – 3.44] | 1.15 (0.79- 1.68) | 0.459 |  |  |
|  | 3rd [3.45 – 3.98] | 1.09 (0.74- 1.61) | 0.653 |  |  |
|  | 4th [3.99 – 12.65] | 1.41 (1.00- 2.00) | 0.053 |  |  |
| **Prothrombin time (baseline)**  | 1st [0.80 – 1.18] | Reference |  |  |  |
|  | 2nd [1.19 – 1.47] | 0.89 (0.63- 1.27) | 0.527 |  |  |
|  | 3rd [1.48 – 2.09] | 0.69 (0.49-0.98) | 0.040 |  |  |
|  | 4th [2.10 – 2.99] | 0.63 (0.44- 0.90) | 0.010 |  |  |
| **Serum calcium (baseline)** | 1st [6.0 – 7.9] | Reference |  | Reference |  |
|  | 2nd [8.0 – 8.4] | 0.64 (0.46-0.88) | 0.006 | 1.06 (0.72-1.57) | 0.764 |
|  | 3rd [8.5 – 8.8] | 0.30 (0.20-0.44) | <0.001 | 0.87 (0.35-0.94) | 0.026 |
|  | 4th [8.9 – 10.9] | 0.26 (0.18-0.38) | <0.001 | 0.64 (0.38-1.08) | 0.092 |
| **Serum phosphorus (baseline)** | 1st [0.9 – 2.8] | Reference |  |  |  |
|  | 2nd [2.9 – 3.2] | 0.65 (0.45 - 0.93) | 0.017 |  |  |
|  | 3rd [3.3 – 3.7] | 0.65 (0.47 - 0.91) | 0.012 |  |  |
|  | 4th [3.8 – 9.9] | 0.63 (0.44 - 0.90) | 0.012 |  |  |
| **Serum protein (baseline)** | 1st[3.5 – 5.8] | Reference |  |  |  |
|  | 2nd [5.9 – 6.4] | 0.40 (0.28 - 0.57) | <0.001 |  |  |
|  | 3rd [6.5 – 7.0] | 0.33 (0.23 - 0.47) | <0.001 |  |  |
|  | 4th[7.1 – 8.7] | 0.21 (0.14 - 0.31) | <0.001 |  |  |
| **Serum albumin (baseline)** | 1st [1.1 – 3.1] | Reference |  | Reference |  |
|  | 2nd [3.2 – 3.6] | 0.43 (0.31 - 0.61) | <0.001 | 0.46 (0.31- 0.67) | <0.001 |
|  | 3rd [3.7 – 4.0] | 0.26 (0.18 - 0.38) | <0.001 | 0.27 (0.18-0.42) | <0.001 |
|  | 4th [4.1 – 5.3] | 0.15 (0.10 - 0.22) | <0.001 | 0.19 (0.12-0.30) | <0.001 |
| **Serum cholesterol (baseline)** | 1st [35 – 118] | Reference |  |  |  |
|  | 2nd[119 – 151] | 0.72 (0.49-1.04) | 0.082 |  |  |
|  | 3rd [152 – 182] | 0.58 (0.40- 0.83) | 0.003 |  |  |
|  | 4th [183 – 334] | 0.39 (0.26-0.59) | <0.001 |  |  |
| **ALP****(baseline)** | 1st [20 – 61] | Reference |  |  |  |
|  | 2nd[62 – 78] | 1.06 (0.69-1.61) | 0.792 |  |  |
|  | 3rd [79 – 102] | 1.61 (1.09- 2.38) | 0.017 |  |  |
|  | 4th [103 – 588] | 2.03 (1.38-2.99) | <0.001 |  |  |
| **AST (GOT)****(at INR>3.0)** | 1st [7 – 19] | Reference |  | Reference |  |
|  | 2nd[20 – 25] | 1.03 (0.67-1.57) | 0.908 | 1.12 (0.70- 1.79) | 0.646 |
|  | 3rd [26 – 37] | 1.12 (0.74- 1.70) | 0.595 | 1.43 (0.90-2.27) | 0.130 |
|  | 4th [38 – 7002] | 2.69 (1.86-3.88) | <0.001 | 2.29 (1.51-3.46) | <0.001 |
| **ALT (GPT)****(at INR>3.0)** | 1st [3 – 14] | Reference |  |  |  |
|  | 2nd[15 – 21] | 0.74 (0.50-1.10) | 0.142 |  |  |
|  | 3rd [22 – 36] | 0.86 (0.58- 1.27) | 0.447 |  |  |
|  | 4th [37 – 6800] | 1.62 (1.13-2.31) | 0.008 |  |  |

\* Covariates: gender, age, comorbidities including diabetes mellitus, coronary artery disease, atrial fibrillation, deep vein thrombosis, congestive heart failure, and CKD stage, and laboratory findings including INR at baseline and at INR > 3.0, baseline serum calcium, phosphorus, protein, albumin, cholesterol, and alkaline phosphatase level.

OR, odds ratio; CI, confidence interval